Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy
Human Gene Therapy · 2026
DOI: 10.1177/10430342251385586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Madhurima Saha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Duchenne Research Fund.
Abstract (Originalsprache)
Significant progress has been made in gene therapy for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting pediatric patients. However, the immune responses triggered by high-dose systemic delivery of adeno-associated virus (AAV) vectors remain a major challenge. These responses include the generation of long-lasting anti-capsid antibodies and potential immunity against the therapeutic transgene, rendering gene therapy ineffective. In addition, pre-existing anti-AAV antibodies exclude patients from eligibility for treatment. To address these limitations, we have developed an immunosuppression (IMS) strategy aimed at mitigating immune responses to the AAV capsid while enhancing microdystrophin expression. Using an optimized expression cassette (AAV9-UFµDys1) for sustained microdystrophin expression in striated muscle and heart, we observed a 40% improvement in muscle force compared with animals receiving a GFP-encoding control AAV9 vector. In mdx mice, a single-dose IMS regimen significantly increased microdystrophin expression in cardiac and skeletal tissues and repeat dosing further enhanced expression, an effect not observed in non-IMS-treated mdx mice. To model pre-existing immunity, we immune-challenged wild-type mice with empty AAV9 capsids and tracked antibody responses over time. The IMS regimen effectively reduced total anti-AAV antibody levels and increased microdystrophin expression in UFµDys1-treated mice. These findings highlight the potential of IMS to minimize immune barriers, facilitate repeat AAV administration, and expand the therapeutic window for DMD gene therapy. Our results support the further development of AAV-mediated approaches using either microdystrophin-expressing vectors or next-generation systems delivering full-length or near-full-length dystrophin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA.
- Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Förderung
- NINDS NIH HHS
- Duchenne Research Fund
Zitieren
APA
Saha, M., Bhake, R., Meyers, C. A., Coleman, K., Trivedi, P. D., Gallman, M., Biswas, M., Herzog, R. W., Byrne, B. J., & Corti, M. (2026). Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy. Human Gene Therapy. https://doi.org/10.1177/10430342251385586
Vancouver
Saha M, Bhake R, Meyers CA, Coleman K, Trivedi PD, Gallman M, et al. Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy. Human Gene Therapy. 2026. doi:10.1177/10430342251385586
BibTeX
@article{Saha2026,
author = {Saha, Madhurima and Bhake, Radhika and Meyers, Craig A and Coleman, Kirsten and Trivedi, Prasad D and Gallman, Mitch and Biswas, Moanaro and Herzog, Roland W and Byrne, Barry J and Corti, Manuela},
title = {Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342251385586}
}
EUVIMED